|
|
Adverse Events
Incidence of serious adverse events in all CIMZIA clinical trials (per 100 patient-years)1
In completed and ongoing clinical studies (CIMZIA, n=5118)*:
- Tuberculosis: CIMZIA, 0.61 vs placebo, 0
In all clinical trials (CIMZIA, n=4650; placebo, n=1319)*:
- Malignancies: CIMZIA, 0.5 (0.4, 0.7)† vs placebo, 0.6 (0.1, 1.7)†
In CIMZIA RA clinical trials (CIMZIA, n=2367)*:
- A total of 3 cases of lymphoma were observed
Treatment-Emergent Adverse Reactions Reported by ≥3% of Patients Treated with CIMZIA Dosed Every Other Week During the Placebo-Controlled Period of Rheumatoid Arthritis Studies with Concomitant Methotrexate1
Click to enlarge
- In RA clinical trials, 5% of patients discontinued taking CIMZIA therapy due to adverse events vs 2.5% for placebo
- Patients receiving CIMZIA 400 mg as monotherapy every 4 weeks in RA-controlled clinical trials had similar adverse reactions to those patients receiving CIMZIA 200 mg every 2 weeks
Reference:
1. CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.
|
|
Your patients may be
eligible to save up to
$500 per pack on
CIMZIA prescriptions
|
 |
